Back to top
more

Perrigo (PRGO)

(Delayed Data from NYSE)

$27.69 USD

27.69
1,056,559

-0.49 (-1.74%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $27.72 +0.03 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 40% and 2.76%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Perrigo (PRGO) Down 11.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Perrigo (PRGO) Beats on Q2 Earnings & Sales, Reiterates '23 View

by Zacks Equity Research

Perrigo (PRGO) reports encouraging second-quarter 2023 results. Management reaffirms the financial guidance for 2023.

Perrigo (PRGO) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Perrigo (PRGO) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Perrigo (PRGO) delivered earnings and revenue surprises of 16.67% and 0.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

QIAGEN (QGEN) Expands Digital PCR Offering With New Pact

by Zacks Equity Research

QIAGEN (QGEN) and Niba Labs can assist companies developing cell and gene therapies to overcome significant resource limitations and adhere to stringent project deadlines.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on stronger base volume recovery and growth from strategic acquisitions.

Boston Scientific (BSX) Gets FDA Nod for Vercise Software

by Zacks Equity Research

Boston Scientific's (BSX) Vercise Neural Navigator 5 Software has an improved user interface that presents patient data in an easier-to-understand style and enables better therapy delivery.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on strategic acquisitions and robust performance of the DSA and RMS arms.

Hyperfine (HYPR) ACTION PMR Study Targets Better Stroke Care

by Zacks Equity Research

Hyperfine's (HYPR) ACTION PMR study focuses on utilizing point-of-care brain imaging to identify strokes and salvageable brain tissue.

Perrigo (PRGO) Gets FDA Nod for First OTC Birth Control Pill

by Zacks Equity Research

Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.

Glaukos (GKOS) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

DexCom (DXCM) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Abhinab Dasgupta headshot

3 Healthcare Stocks to Buy Amid Market Volatility

by Abhinab Dasgupta

Patterson (PDCO), Perrigo (PRGO) and GSK are three healthcare stocks that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.

Should Value Investors Buy Perrigo (PRGO) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Stryker (SYK) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

PacBio (PACB) Gets New Order for Revio System From Bioscientia

by Zacks Equity Research

PacBio (PACB) receives new order for its Revio system from Bioscientia that will boost the latter's services. Here's how Revio can help Bioscientia improve diagnosis and treatment for monogenic disorders.